The ability of radiolabelled gonadotrophin-releasing hormone (GnRH) and GnRH analogues to bind to homogenates and membranes of rat, rabbit and sheep pituitary and to luteal homogenates and membranes from a number of species was measured. In addition, inactivation of tracer during binding incubation was estimated by measurement of the ability of the unbound tracer fraction to bind to fresh GnRH-receptor or anti-GnRH antibody-Following incubation of rat, sheep and rabbit pituitary gland with a radiolabelled GnRH agonist tracer, appreciable amounts of specific binding of GnRH agonist to fresh rat pituitary or human placental GnRH receptors could still be demonstrated. In contrast, no specific binding of [ 125 l]-labelled GnRH analogues were measured following incubation of the tracer with homogenates or membranes of bovine, sheep and porcine luteal tissue, nor with rabbit and rat placental homogenates. However, during incubation of GnRH tracers with these tissues, almost complete inactivation of GnRH tracers occurred. There was an inverse relationship between binding and inactivation of [ 125 l]-labelled GnRH for a number of human corpora lutea. We conclude that degradation of GnRH tracers may prevent the measurement of specific GnRH binding sites in some tissues.
Introduction
Specific, high-affinity binding sites for gonadotrophinreleasing hormone (GnRH) and GnRH analogues are readily demonstrable in the mammalian pituitary gland (Clayton and Catt, 1981; Nett et al, 1987; Hazum and Conn, 1988) and in the rat gonads (Reeves et al, 1980; Sharpe and Fraser, 1980) . Specific binding sites for GnRH were also demonstrable in the human ovary (Bramley et al, 1985; Marchetti et al, 1986; Latouche et al, 1989) and placenta (Currie et al, 1981; Belisle et al, 1984; Belisle et al, 1986; Iwashita et al, 1986; , though these binding sites were of 'low affinity' relative to pituitary receptors, and did not discriminate between GnRH and GnRH agonist analogues. Similar 'low affinity' GnRH binding sites have been demonstrated recently in human cancers of the prostate (Kadar et al, 1988) , endometrium (Pahwa et al, 1991) , breast (Eidne et al, 1985; Fekete et al, 1989) and ovary Pahwa et al, 1989) . In contrast, specific GnRH binding sites could not be demonstrated in the corpus luteum of other species (Asch et al, 1981; Clayton and Huhtaneimi, 1982; Brown and Reeves, 1983) and some species appeared to be insensitive to the antigonadal effects of GnRH (Thau et al, 1985) . However, other studies have shown GnRH binding and direct effects of GnRH analogues in vitro to ovarian cells of these species (see Bramley, 1989 for review) . One possible cause of the inability to demonstrate binding sites may be rapid inactivation of GnRH tracers. Indeed, we have shown that radioiodinated GnRH analogues and isoforms can be rapidly inactivated © European Society for Human Reproduction and Embryology by rat pituitary and human placental tissues under binding incubation conditions Triplicate aliquots (100 ul) of two mid-luteal phase human corpora lutea, and three porcine and ovine corpora lutea and rabbit placentae were incubated with 600 000 c.p.m. of [ 123 I]-labelled gonadotrophin-releasing hormone (GnRH) agonist (buserelin) or [' M I]-labelled GnRH isoforms for 1 h at 20°C (placenta) or at 4*C for 4 h (pituitaries), with and without excess GnRH agonist and centrifuged at 30 000 g for 10 min at 4°C. Pellets were counted for [ l25 I]-labelled tracer bound specifically and supernatants were adjusted to 90 000 c.p.m. per ml, and incubated with fresh rat pituitary or with human placental membranes or adjusted to 20 000 c.p.m. per ml and incubated with anti-GnRH antibody (GnRH Ab; EL 14, 1:50 000). Tracer bound specifically was expressed as a percentage of unincubated controls. ography on Sephadex G25 columns (1X40 or 1x60 cm) in 0.01 M acetic acid-0.1 % bovine serum albumin (BSA). Specific activity of binding was calculated for each GnRH isoform or analogue tracer preparation as described previously .
Tissue preparation
Rat pituitary glands were obtained from immature (28-35 day) female Sprague-Dawley rats killed by CO2 asphyxiation. Pituitary glands were homogenized in ice-cold 0.3 M sucrose-10 mM Tris-HCl-1 mM EDTA, pH 7.4 (SET medium; 0.5 ml/rat pituitary) using 12 strokes of a loose Dounce homogenizer, filtered through cheesecloth, and fractionated immediately, or snap-frozen in solid CO2 in 2 ml aliquots, and stored at -20°C until required. Sheep pituitaries were dissected from immature female sheep heads obtained from a local abattoir within 1 h of slaughter, minced and homogenized (10 ml SET medium/g sheep pituitary) using a Polytron (Kinematica, Lucerne, Switzerland) homogenizer at full speed (two bursts of 10 s interspersed with a 1 min cooling period in ice).
Mid-luteal phase sheep, cow and pig ovaries were obtained from a local abattoir within 1 h of slaughter. Corpora lutea were dissected free of connective tissue and stroma, minced with scissors and homogenized in ice-cold SET medium (10 ml/g) using a Polytron homogenizer (two 10 s bursts, interspersed with a 1 min cooling period in ice). Aliquots (2 ml) were stored frozen (-20°C) until required.
Porcine granulosa cells were aspirated from fresh small (1-3 mm diameter) and medium (3-5 mm diameter) follicles (4°C) using a narrow-gauge needle. Follicular fluid was centrifuged at 1000 g for 5 min, and cells were washed twice with 10 volumes of ice-cold phosphate-buffered saline (Dulbecco's; Flow Laboratories, Irvine, UK). Cells were homogenized (10 ml SET/ml packed cell volume) using 12 complete strokes of a loose-fitting Dounce homogenizer.
Seven mid-luteal phase human corpora lutea were obtained from women undergoing laparotomy for non-endocrine conditions (Bramley et al., 1987) , processed as described previously and stored in liquid nitrogen for up to 18 months. We have shown previously that such storage has no effect on receptor measurements (Bramley et al., 1987) .
Placental tissue was obtained from women undergoing elective Caesarian section at term. Tissues were homogenized and membrane fractions prepared as described previously .
Differential rate centrffugation
Homogenates were centrifuged at 1000 g for 10 min (4°C) and the pellet resuspended gently in SET medium. Supernatants were respun at 50 000 g for 60 min in a Sorvall OTD-50 refrigerated ultracentrifuge. Supernatants were discarded, and pellets (membranes) were gently resuspended in SET medium (loose Dounce) and stored in 2 ml aliquots at -20°C.
Measurement of GnRH binding to tissue fractions
Triplicate aliquots (20-200 u.1) of tissue fractions were incubated in a 1 ml system containing 40 mM Tris-HCl, pH 7.4, 0.5% bovine serum albumin (BSA) and 100 000 c.p.m. of [ 123 I]-labelled GnRH tracer. After incubation under the appropriate conditions (for rat, sheep pituitary and other tissues, 4 h at 4°C; for human placenta, 1 h at 20°C), bound hormone was recovered by polyethyleneglycol precipitation (Bramley el al., 1985) , and [ l25 l] bound to the pellet counted in a Packard 'Crystal' y-counter at an efficiency of 75%. Non-specific binding was measured in duplicate in the presence of 1 |ig (pituitary) or 10 |ig (placenta and other tissues) unlabelled buserelin (normally 3-5% of total counts added). The difference between binding in the presence and absence of unlabelled GnRH agonist represented specific binding (normally 10-35% total counts added). Positive controls (rat pituitary; human placental membranes) were always included in each binding asay. Controls without tissue, with and without unlabelled GnRH agonist, were also included to correct for displacement of tracer from assay tubes by cold analogue (0.5-2% of total counts added).
Binding of [
l25 r]-labelled GnRH isoform tracers (20-30 000 c.p.m. added) to anti-GnRH antibody (EL 14 anti-GnRH antibody; final dilution, 1:10 000-1:50 000) was performed in the presence or absence of unlabelled hormone (10 |ig). Incubation was for 6 h at 4°C. Icecold bovine y-globulin (0.5 ml; 0.5%) was added and bound hormone recovered by polyethyleneglycol (PEG) precipitation (Bramley et al., 1985) .
Inactivation of GnRH tracers
Inactivation of radiolabelled GnRH tracers was measured as described previously . Briefly, quintuplicate aliquots of tissue fractions were incubated with 600 000 c.p.m. of [ 125 I]-labelled GnRH analogue or isoform tracer under the usual incubation conditions for each tissue. Tubes were chilled in ice and centrifuged at 30 000 g for 5 min. Supernatants were aspirated, and pellets and supernatants counted for I25 I in a NE 1600 y-counter at an efficiency of 75%. The volume of each supernatant was adjusted with incubation buffer to give 90 000-100 000 c.p.m./ ml, and triplicate aliquots (1 ml) were incubated with fresh rat pituitary homogenate (50 ui) for 4 h at 4°C, with or without 1 |ig unlabelled agonist to measure non-specific binding. After the second incubation, bound GnRH tracer was recovered by polyethyleneglycol precipitation, and pellets counted for bound [ l25 I]-GnRH agonist. Three controls were always included: (i) tracer incubated with tissue at 0°C during the first incubation; and incubation of tracer without tissue fractions at (ii) 0°C or at (iii) 37°C. All three supernatants were tested for binding in the second incubation, and values agreed to within ± 8%. Inactivation of GnRH tracer during the first incubation was reflected by a reduction in specific binding in the second incubation, and was expressed as a percentage loss of binding relative to controls.
Protein was measured by the method of Lowry et al. (1951) .
Results
As reported previously , the amount of GnRH agonist analogue binding to membrane fractions from rat pituitary was high, but other isoforms of GnRH were not bound appreciably (Table I) . Similarly, binding was also high with ovine pituitary (Table I) and rabbit pituitary membranes (not shown). In contrast, human placental membranes bound salmon GnRH (s GnRH) and chicken GnRH II (ch GnRH II) in addition to GnRH agonist tracers, with intermediate binding levels of mammalian (m) GnRH. Ch GnRH I (ch GnRH I) and lamprey (1) GnRH were not bound well (Table I ). The differential binding of these tracers was not due to differences in tracer inactivation during incubation, as appreciable amounts of binding were observed for all unbound tracers following their subsequent incubation with either rat pituitary or human placental membranes (GnRH agonist), with human placental membranes or anti-GnRH antibody (s GnRH; ch GnRH II), or with antibody (ch GnRH I; m GnRH; 1 GnRH) ( Table I) . Levels of inactivation measured using different techniques (e.g. human placental receptor and antibody for s GnRH and ch GnRH II; rat pituitary and human placenta for GnRH agonist) corresponded well.
Specific binding of [ I25 I]-labelled GnRH analogue or isoforms was unmeasurable following incubation of tracers with rabbit placenta, or with ovine or porcine luteal membranes (Table II) . However, inactivation of GnRH tracers during incubation with these tissues was extensive, and little tracer was capable of rebinding to fresh membranes or anti-GnRH antibody after incubation with these tissues. Similar results were also obtained for bovine corpus luteum, porcine granulosa cells and rat placenta (data not shown). Human corpus luteum homogenates bound GnRH agonist to differing extents, and showed low binding of s GnRH and ch GnRH n, but not other isoforms (Table IT) . Moreover, moderate levels of tracer binding were observed following reincubation of unbound tracer with fresh receptor or antibody.
Studies with a number of human corpus luteum homogenates showed a significant inverse correlation between levels of [ l25 I]-labelled GnRH agonist bound and GnRH agonist tracer inactivation during incubation. When levels of I25 Ilabelled GnRH agonist binding to luteal preparations were high, low levels of tracer inactivation were found in the second binding incubation; conversely, when GnRH binding was low, levels of tracer inactivation were high (Figure 1 ; R 2 = -0.61; P < 0.01).
Discussion
GnRH-like peptides are well established as paracrine regulators of gonadal function in the rat (Currie and Leung, 1993; Sharpe, 1994) , and specific, high affinity receptors for GnRH and its analogues are present in rat gonadal cells (Reeves et al, 1980; Sharpe and Fraser, 1980 ) which appear to be identical to pituitary GnRH receptors (Hazum and Nimrod, 1982; Iwashita and Catt, 1985; Catt et al, 1993) . GnRH effects are demonstrable in human placenta and ovary (Kang et al, 1991; Currie and Leung, 1993; Guerrero et al, 1993) , GnRH binding sites are present in these tissues (Bramley, 1989; , and there is expression of mRNA for GnRH (Duello et al., 1993) and GnRH-receptor in these tissues (Peng et al, 1994; Lin et al, 1995) . However, the presence of GnRH binding sites in extrapituitary tissues of other species is disputed. Moreover, whereas some groups have been unable to show GnRH binding in ovarian tissues from some species, the presence of gonadal GnRH-like factors and GnRH effects on gonadal function, can be demonstrated in these same species (Bramley, 1989; Currie and Leung, 1993) . Our present results suggest that degradation of GnRH tracer during GnRH-binding incubations may be responsible in part for a failure to demonstrate binding sites in tissues from these species.
Tissues which bound GnRH and its analogues well (rat and sheep pituitary; human placenta) showed low levels of tracer inactivation when unbound tracer fractions were incubated with fresh receptor or anti-GnRH antibody (Table I ). In contrast, ovarian tissues from porcine, ovine and bovine ovaries failed to bind GnRH isoforms or analogues appreciably; however, inactivation of GnRH tracers during assay incubations was almost complete (Table IT) . Two human corpora lutea from the mid-luteal phase of the menstrual cycle bound GnRH agonist analogues, and showed low binding of s GnRH and ch GnRH II, similar to placental GnRH receptors . Moreover, studies with seven human corpora lutea demonstrated that corpora lutea which showed high binding of GnRH agonist tracers had low tracer inactivation during incubation, whereas corpora lutea with low GnRH agonist binding had high inactivation (Figure 1 ). We noted previously that the levels of GnRH agonist binding to human corpora lutea from the same stage of the luteal phase varied markedly (Bramley et al, 1987) . The present study suggests that one cause of this variability between different corpora lutea at the same stage of the cycle may be differences in tracer inactivation rates. Whether GnRH binding sites can be demonstrated in gonadal tissues from other species or not (Brown and Reeves, 1983; Bramley, 1989) will depend on the development of GnRH agonists and/ or assay incubation conditions which prevent GnRH tracer inactivation under the conditions used for the binding assay. Inactivation of GnRH tracers by human placental tissue extracts appears to be due to the concerted action of a variety of proteases of differing specificity, and inclusion of an appropriate cocktail of specific protease inhibitors can prevent GnRH tracer degradation during binding incubation (T.A. Bramley, C.A. McPhie and G.S. Menzies, unpublished data). However, the ultimate proof for the existence of GnRH receptors in ovarian tissues of these species will be the demonstration of the expression of GnRH-receptor mRNA.
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